Fresenius Medical Care stock at EUR 38.23, down 0.86% premarket
Published on 11/19/2026 at 08:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target cut weighs on outlook
- Berenberg lowered its Fresenius Medical Care target to EUR 37 from EUR 42 while keeping a Neutral rating.
- The company provides dialysis care and kidney-related products through care delivery and care enablement activities.
- MarketScreener lists February 22 as the next Q4 2026 earnings release date.
Fresenius Medical Care stock traded at EUR 38.23 on Lang & Schwarz at 08:17 CET on Thursday, November 19, 2026, 0.86 percent below the Xetra close of Wednesday, November 18, 2026, at EUR 38.56.
The premarket indication follows a fresh analyst move. Berenberg analyst Harry Gillis maintained a Neutral recommendation on November 18 and lowered the price target for Fresenius Medical Care from EUR 42 to EUR 37, according to MarketScreener. The revised target is below the latest Xetra close, while the recommendation remains unchanged.
Dialysis care remains the core business
Fresenius Medical Care provides dialysis treatment and kidney-care products worldwide. Its business covers care delivery as well as the development and supply of dialysis equipment and related products, giving investors exposure to both clinical services and medical technology.
MarketScreener lists February 22 as the scheduled release date for the company's fourth-quarter 2026 results. That update will provide the next major opportunity to assess operating momentum and management's outlook.
European equities are monitored through current market reports.
